ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

US · FDA approval, new medicine

Gefurulimab-gaks (Klygefa)

To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

In 260 adults with AChR antibody-positive generalised myasthenia gravis, weekly subcutaneous gefurulimab improved MG-ADL score at 26 weeks vs placebo (−4.2 vs −2.6; difference −1.6, P<.001); QMG also improved; adverse events were similar. RCT · phase 3 · n = 260 · JAMA Neurol · 2026

Approved 13 Nov 2026
EU · CHMP positive opinion

Gefurulimab (Klygefa)

Treatment of adult patients with generalised myasthemia gravis (gMG)

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

In 260 adults with AChR antibody-positive generalised myasthenia gravis, weekly subcutaneous gefurulimab improved MG-ADL score at 26 weeks vs placebo (−4.2 vs −2.6; difference −1.6, P<.001); QMG also improved; adverse events were similar. RCT · phase 3 · n = 260 · JAMA Neurol · 2026

CHMP opinion 17 Sept 2026 · Alexion Europe

Research

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.